New Jersey CyberKnife Develops Training Program for Multidisciplinary Approach to Lung Cancer Treatment

Lung cancer patients seeking treatment at New Jersey CyberKnife will soon experience a more collaborative approach to the planning and delivery of their treatment, including the participation of not only CyberKnife specialists, but also their referring doctors.

New Jersey CyberKnife at the J. Phillip Citta Regional Cancer Center is developing a CyberKnife training program to encourage physicians to remain involved in their patients’ care from initial consultation to post-treatment follow-up.

“The program is aimed at providing better continuity of care for patients with lung cancer and affords a patient’s doctor ongoing involvement in the treatment process,” said Dr. David D’Ambrosio, medical director of New Jersey CyberKnife. “This is particularly important for thoracic oncology patients who can benefit from the continued involvement of the physician with the most knowledge of their medical history.”

New Jersey CyberKnife treats lung cancer with a procedure called stereotactic body radiation therapy (SBRT). Using CyberKnife® technology, radiation is delivered to the targeted tumor location with pinpoint precision, and radiation exposure to surrounding healthy tissue is minimized. Planning and delivery of CyberKnife SBRT procedures typically involve specialists from varied backgrounds working together to determine the most appropriate course of treatment for each patient.

According to Dr. D’Ambrosio, the addition of the CyberKnife training program for lung specialists supports multidisciplinary collaboration in providing quality patient care.

The new approach will work in combination with hospital partner Community Medical Center’s lung disease-specific tumor board. Patients who participate in this program are confidentially evaluated by a multidisciplinary team of experts, including thoracic surgeons, medical and radiation oncologists, pulmonologists, radiologists, pathologists and nurses from the hospital.

“This is a unique opportunity for lung cancer patients, particularly those with more complex cases,” said Dr. D’Ambrosio.